Sapu Bioscience today announced advancements in its global IP portfolio supporting OT-101, its proprietary TGF-β antisense therapeutic platform, strengthening protection across neurology, oncology, ...
A novel 89Zr-a-PD-1 immuno-PET-CT may improve pseudoprogression detection in a lung cancer murine model receiving immunotherapy. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I.
Schematic representation of different strategies targeting TGF-β signaling for liver fibrosis therapy. TGF-β signaling inhibitors hold important therapeutic potential for hepatic fibrosis. Although ...
Henan Medinno Pharmaceutical Technology Co. Ltd. has synthesized TGF-β receptor type-1 (TGFBR1; ALK5; SKR4; TβR-I) inhibitors reported to be useful for the treatment of cancer, aging, arteriosclerosis ...
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and Bristol-Myers Squibb Company (NYSE: BMY) today announced that they have entered into a collaboration agreement for the discovery, development and ...
Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancer Planned initiation of ...
CYR61, cysteine-rich angiogenic inducer 61; FT, factors of transcription; LATS, large tumor suppressor; MOB, mob kinase activator; MST, mammalian sterile 20-like ...
In a human organoid-based mechanistic investigation, researchers revealed how an immunosuppressive drug, antithymocyte globulin (ATG), induces injury to blood vessels in the liver. According to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results